Selective inhibition of JAK1 by upadacitinib targets specific pathways involved in AD, differentiated from first-generation pan-JAK inhibitors such as tofacitinib and ruxolitinib, which inhibit multiple JAK pathways (14). This evidence concerns the gene JAK1 and Alzheimer disease.